May 2020
Conyers provided Cayman Islands and British Virgin Islands legal advice to Kintor Pharmaceutical Limited (the “Company”) in connection with its HK$1 billion initial public offering of 92,347,500 shares on the Main Board of The Stock Exchange of Hong Kong (Stock code: 9939).
The Company is a clinical-stage novel drug developer in China focused on the proprietary R&D of potential first-in-class and best-in-class drugs for cancers and other androgen receptor-related, or AR-related diseases.
Partner Richard Hall and Counsel Angie Chu of Conyers’ Hong Kong office advised on the matter, working alongside Ashurst Hong Kong and Slaughter and May.